Sarepta Therapeutics announced a new employment agreement with Michael Severino M.D. effective July 28, 2026, to serve as the company's Chief Executive Officer and Board member. This move signals a planned leadership transition and serves to provide continuity for the biopharmaceutical company's strategic direction.